CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 46 enrolled
Drug / intervention
PF-00337210 +9 moredrug
Likely dose
PF-00337210 0.67mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01105533
NCT01105533Phase 1Completed
CompareCT.gov

Phase I, Open-Label, Multi-Center, Accelerated Dose Escalation Study Of The Anti-Angiogenesis Agent PF-00337210 In Patients With Advanced Solid Tumors

Pfizer·interventional·Posted Apr 16, 2010·Updated Mar 19, 2013

In Brief

A Phase 1 clinical trial evaluating PF-00337210 for Neoplasm. Completed, enrolled 46 participants across 3 sites.

Detailed Summary

This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm
CountriesUnited States
CollaboratorsUniversity of Wisconsin, Madison

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 16, 2010
Enrollment StartMay 1, 2006
Primary CompletionOct 1, 2010
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.2 years ago

Interventions

PF-00337210drug

0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous

PF-00337210drug

1mg Capsule Once Daily (Dose Escalation) Continuous

PF-00337210drug

2mg Capsule Once Daily (Dose Escalation) Continuous

PF-00337210drug

4mg Capsule Once Daily (Dose Escalation) Continuous

PF-00337210drug

6mg Capsule Once Daily (Dose Escalation) Continuous

PF-00337210drug

9mg Capsule Once Daily (Dose Escalation) Continuous

PF-00337210drug

8mg Capsule Once Daily (Dose Escalation) Continuous

PF-00337210drug

4mg Capsule Twice Daily (Dose Escalation) Continuous

PF-00337210drug

6mg Capsule Twice Daily (Dose Escalation) Continuous

PF-00337210drug

6mg Capsule Twice Daily (Dose Expansion) Continuous